Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 40Cisplatin 35pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Drug Therapy 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Oxaliplatin 3Imatinib Mesylate 3Fluorouracil 3Cerebral Decortication 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Blood Component Removal × Other solid neoplasm × Clear all
NCT04981119 2026-06-02

BASECAMP-1

A2 Biotherapeutics Inc.

Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡